Search

Displaying results 4521 - 4530 of 6198 in total
  1. Drug

    Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB15500
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15508
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  3. Drug

    Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15519
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Synonyms: Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (UV, formaldehyde inactivated)
  4. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15564
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  5. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061] It is administered by direct injection into superficial, deep, or visceral tumors. … cells, causing tumor lysis and release of tumor and viral antigens, with the GALV-GP-R– glycoprotein enhancing direct tumor killing and GM-CSF promoting dendritic cell and monocyte activation to drive an

  6. Drug

    Ertiprotafib

    go.drugbank.com/drugs/DB06521
    Experimental

    In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.

  7. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was...

  8. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy. … It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous

  9. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as [ISS-1018]), for use with its vaccine.

  10. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV.